Could a cheap blood thinner cut stroke risk in africa?
NCT ID NCT06919835
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug cilostazol can prevent recurrent strokes and heart problems in 1100 recent stroke survivors in Ghana. Participants take either cilostazol or a placebo twice daily for 24 months. The goal is to see if this affordable drug, already used in Asia, can reduce major cardiovascular events in a high-risk African population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cilostazol (a blood-thinning drug that helps prevent blood clots)
- What this could lead to
- If it works, this could provide an affordable and effective way to prevent recurrent strokes in low-resource settings like sub-Saharan Africa.
- What could go wrong
- This trial is still recruiting and results are not yet available. Previous promising data came mainly from Asian populations, so it may not work as well in Africans. Side effects like bleeding are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 1,100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Above the age of 30 years; male or female (sex is a biological variable of interest) 2. Ischemic stroke or high-risk TIA (ABCD2 score \>= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset) 3. Aspirin or clopidogrel monotherapy 4. Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension \>140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction 5. Legally competent to sign informed consent or have a LARs who is able to provide consent for them 6. In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up. 7. Able to do labs at all study intervals (7 visits total) Exclusion Criteria: 1. Unable to provide a valid informed consent 2. Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.) 3. Hemorrhagic stroke survivor within the last 2 years 4. Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation) 5. On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy) 6. Modified Rankin Scale 5 7. Thrombocytopenia (platelet count \<1000,000) 8. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C) 9. Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity) 10. Nursing/pregnant mothers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High-risk transient ischemic attack are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Kwame Nkrumah University of Science & Technology
Kumasi, Ghana
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Zapping the spine while wearing a robotic ankle: a new way to help kids walk?
- Can a nurse and a neighbor help tame chronic disease?
- Can PET scans reveal hidden heart inflammation after a stroke?
- Two ways to catch a hidden heart rhythm after stroke